- Home
- EPIX vs ZURA Comparison
EPIX vs ZURA Comparison
Compare EPIX & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- ZURA
- Stock Information
- Founded
- EPIX 2009
- ZURA 2022
- Country
- EPIX Canada
- ZURA United States
- Employees
- EPIX N/A
- ZURA N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPIX Health Care
- ZURA Health Care
- Exchange
- EPIX Nasdaq
- ZURA Nasdaq
- Market Cap
- EPIX 71.5M
- ZURA 76.6M
- IPO Year
- EPIX N/A
- ZURA N/A
- Fundamental
- Price
- EPIX $1.71
- ZURA $1.01
- Analyst Decision
- EPIX Hold
- ZURA Buy
- Analyst Count
- EPIX 3
- ZURA 7
- Target Price
- EPIX $2.00
- ZURA $14.33
- AVG Volume (30 Days)
- EPIX 129.2K
- ZURA 517.4K
- Earning Date
- EPIX 05-08-2025
- ZURA 05-08-2025
- Dividend Yield
- EPIX N/A
- ZURA N/A
- EPS Growth
- EPIX N/A
- ZURA N/A
- EPS
- EPIX N/A
- ZURA N/A
- Revenue
- EPIX N/A
- ZURA N/A
- Revenue This Year
- EPIX N/A
- ZURA N/A
- Revenue Next Year
- EPIX N/A
- ZURA N/A
- P/E Ratio
- EPIX N/A
- ZURA N/A
- Revenue Growth
- EPIX N/A
- ZURA N/A
- 52 Week Low
- EPIX $1.40
- ZURA $0.97
- 52 Week High
- EPIX $7.88
- ZURA $5.50
- Technical
- Relative Strength Index (RSI)
- EPIX 53.23
- ZURA 35.69
- Support Level
- EPIX $1.60
- ZURA $0.99
- Resistance Level
- EPIX $1.70
- ZURA $1.06
- Average True Range (ATR)
- EPIX 0.05
- ZURA 0.08
- MACD
- EPIX -0.00
- ZURA -0.01
- Stochastic Oscillator
- EPIX 84.62
- ZURA 9.02
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.